Comparative efficacy and acceptability of antidiabetic agents for Alzheimer's disease and mild cognitive impairment: A systematic review and network meta-analysis.

Cao B, Rosenblat JD, Brietzke E, Park C, Lee Y, Musial N, Pan Z, Mansur RB, McIntyre RS

Diabetes, obesity & metabolism19 Jun 2018Cited by 89 (Europe PMC)

PMID29790638DOI10.1111/dom.13373PepBankPUB-29790638

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study2

No result from this study comes from a test of the peptide.

Studies that did not test the peptide alone2

In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Liraglutide.

01HumanNot a test of Liraglutide aloneSystematic reviewEfficacy outcome
In people with Alzheimer's disease or mild cognitive impairment, pooled antidiabetic agents (liraglutide among them) improved cognition more than placebo.
In plain wordsIn people with Alzheimer's disease or mild cognitive impairment, antidiabetic drugs as a group improved thinking more than placebo.
Peptide
Liraglutide
Outcome
IncreaseCognition with antidiabetic agents versus placebo (pairwise comparisons)
Study
n = 4,855
Comparator
Placebo
Outcome group
Cognition and memory · Nervous system and cognition
Source sentences
Summary
The results of 29 pairwise comparisons indicated that cognition was significantly improved in subjects treated with antidiabetic agents compared with placebo.
1 context sentence(design, population, supporting numbers)
Summary · context
Nineteen eligible studies (n = 4855) evaluating the effects of 6 different antidiabetic drugs (i.e. intranasal insulin, pioglitazone, rosiglitazone, metformin, sitagliptin and liraglutide) were included.
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Report a problemFND-2979063801
02HumanNot a test of Liraglutide aloneSystematic reviewSafety outcome
In people with Alzheimer's disease or mild cognitive impairment, pooled antidiabetic agents (liraglutide among them) did not differ in acceptability from placebo or from each other.
In plain wordsIn people with Alzheimer's disease or mild cognitive impairment, antidiabetic drugs as a group were no less acceptable than placebo or each other.
Peptide
Liraglutide
Outcome
No significant changeAcceptability of antidiabetic agents versus placebo and each other
Study
n = 4,855
Comparator
Placebo or another antidiabetic agent
Outcome group
Patient-reported outcomes · Nervous system and cognition
Source sentences
Summary
No significant differences in acceptability were identified when comparing agents with each other and with placebo.
1 context sentence(design, population, supporting numbers)
Summary · context
Nineteen eligible studies (n = 4855) evaluating the effects of 6 different antidiabetic drugs (i.e. intranasal insulin, pioglitazone, rosiglitazone, metformin, sitagliptin and liraglutide) were included.
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Report a problemFND-2979063802

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
12 Oct 2026, 12:10 UTC
Study results updated
Version 1
9 Oct 2026, 03:05 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

MeSH terms

Keywords

PepBank is a research reference. Talk to a doctor before you use any peptide.